Holen Sie sich die Stockscreener-App
13.75
2.27%
-0.32
Handel nachbörslich:
13.75
Schlusskurs vom Vortag:
$14.07
Offen:
$14.38
24-Stunden-Volumen:
8.72M
Relative Volume:
1.81
Marktkapitalisierung:
$10.67B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-1.21B
KGV:
-8.5729
EPS:
-1.6039
Netto-Cashflow:
$-387.48M
1W Leistung:
+5.12%
1M Leistung:
-14.17%
6M Leistung:
-19.31%
1J Leistung:
-31.80%
1-Tages-Spanne:
$13.56
$14.60
1-Wochen-Bereich:
$12.92
$14.60
52-Wochen-Spanne:
$12.55
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
13.75 | 10.67B | 220.00K | -1.21B | -387.48M | -1.6039 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Eingeleitet | Stifel | Buy |
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Underweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
SMMT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Avoiding Lag: Real-Time Signals in (SMMT) Movement - Stock Traders Daily
Why is SMMT stock tumbling today? - MSN
Summit rebounds after nearly $50M insider purchase - MSN
Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Summit Therapeutics Inc (SMMT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Summit Therapeutics Inc (SMMT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Summit Therapeutics Inc (SMMT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Summit Therapeutics Inc (SMMT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Summit Therapeutics Inc (SMMT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Summit Therapeutics Inc (SMMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Why Summit Therapeutics Is Staying In The Biotechnology Spotlight? - Kalkine Media
Summit Therapeutics: Getting A Foot In The Door Isn't Getting Through It (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Inc. (SMMT) Investor Outlook: Evaluating A Potential 103.85% Upside - DirectorsTalk Interviews
Summit Therapeutics Raises $500 Million in Public Offering to Support Lung Cancer PipelineGAAP Earnings Report - newsline.com
SMMT Jumps As Summit Therapeutics Rides Ivonescimab Momentum - timothysykes.com
Summit Therapeutics stockholders approve directors and incentive plan - The Globe and Mail
Summit Therapeutics (SMMT) Raises $500 Million Through Public Offering - Insider Monkey
Insider Buying: Summit Therapeutics Co-CEO, President & Director Bought US$1.5m Of Shares - simplywall.st
Summit Therapeutics files for $500M common stock offering; shares slide over 9% - MSN
Summit Therapeutics (SMMT) Surges 7% as Bulls Test Key ResistanceRelative Volume - newsline.com
Summit Therapeutics (SMMT) Shares Rebound After Co-CEO's $50M St - GuruFocus
5 Best Buy-the-Dip Stocks to Invest In Now - Insider Monkey
SMMT Jumps As Ivonescimab Trial Success Fuels Financing Drive - StocksToTrade
Summit Therapeutics (NASDAQ: SMMT) investors approve directors and 8M-share incentive plan boost - Stock Titan
Summit Therapeutics co-CEO Zanganeh acquires $49.98m in shares By Investing.com - Investing.com Australia
Summit Therapeutics(SMMT.US) 10% Shareholder Buys US$49.99 Million in Common Stock - Moomoo
Insider Stock Purchases: June 12, 2026 - Quiver Quantitative
Summit Therapeutics co-CEO Zanganeh acquires $49.98m in shares - Investing.com
Co-CEO Mahkam Zanganeh (SMMT) reports spouse’s 3.81M-share open-market buy - Stock Titan
Summit Therapeutics (SMMT) Shares Rebound After Co-CEO's $50M Stock Purchase - GuruFocus
Summit Therapeutics (SMMT) Gains 2.83% as Stock Approaches Key Resistance LevelLow Beta Factor - newsline.com
Summit gains after nearly $50M insider buy (SMMT:NASDAQ) - Seeking Alpha
Summit Therapeutics stock rises after CEO share purchase By Investing.com - Investing.com Canada
Summit Therapeutics stock rises after CEO share purchase - Investing.com
Summit Therapeutics Insider Bought Shares Worth $49,987,200, According to a Recent SEC Filing - Moomoo
Summit Therapeutics co-CEO Robert Duggan buys $49.9m in stock - Investing.com India
Summit Therapeutics co-CEO Robert Duggan acquires 3.81 million shares - StreetInsider
Summit Therapeutics Co-Chief Executive Officer Purchased Shares Worth Over $49M - TradingView
Summit Therapeutics (SMMT) Co-CEO Robert Duggan buys 3.81M shares in open market - Stock Titan
Summit Therapeutics Halts US$500m Offering After Ivonescimab Trial Results - Yahoo Finance
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Summit Therapeutics Inc-Aktie (SMMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 12 '26 |
Buy |
13.12 |
3,810,000 |
49,987,200 |
573,883,879 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Soni Manmeet Singh | COO and CFO |
Jun 04 '26 |
Buy |
14.45 |
50,000 |
722,250 |
3,123,603 |
| Xia Yu | Director |
Oct 21 '25 |
Buy |
18.74 |
533,617 |
9,999,983 |
32,057,147 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):